Compare Innodata Inc (INOD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs TG Therapeutics Inc — how do they compare? Innodata Inc trades at $62.04 (market cap $2.10B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.9× Innodata Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and TG Therapeutics Inc for 16 Days on average.
| INOD | TGTX | |
|---|---|---|
Market Cap | $2.10B | $8.16B |
Volume | 989,493 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $121.50 | $59.06 |
52-Week Low | $34.45 | $26.94 |
Typical Hold Time | 19 Days | 16 Days |
Enterprise Value | $1.86B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $62.04, down 2.17% today, amid a bearish technical signal from moving averages. The company shows strong fundamentals with recent earnings beats, including Q2 2026 EPS of $0.41 versus $0.213 expected, and robust profitability with a 14.66% net income margin. Positive news highlights expansion into motion-capture AI labs and strategic board appointments, supporting growth in AI data services.
Outlook remains positive given earnings momentum and AI sector tailwinds, but risks include high valuation multiples like a P/E of 47.43 and customer concentration. Analyst consensus is bullish with 4 buy ratings, suggesting potential upside if execution continues.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
